| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10057274 | HBV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30003462 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30056268 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30056269 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30020676 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30056270 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30056271 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30056272 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS30056273 | HIV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
| TVIS20037727 | HPV | ENSG00000132155.14 | protein_coding | RAF1 | Yes | No | 5894 | A0A0S2Z4L5 L7RRS6 P04049 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | RAF1 |
|---|---|
| DrugBank ID | DB00398 |
| Drug Name | Sorafenib |
| Target ID | BE0000036 |
| UniProt ID | P04049 |
| Regulation Type | inhibitor |
| PubMed IDs | 16757355; 16890795; 17266941; 17272980; 17296815; 20812347; 18794803; 18852116; 20586710 |
| Citations | Adnane L, Trail PA, Taylor I, Wilhelm SM: Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 2006;407:597-612.@@Gollob JA, Wilhelm S, Carter C, Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol. 2006 Aug;33(4):392-406.@@Huether A, Hopfner M, Baradari V, Schuppan D, Scherubl H: Sorafenib alone or as combination therapy for growth control of cholangiocarcinoma. Biochem Pharmacol. 2007 May 1;73(9):1308-17. Epub 2007 Jan 5.@@Cascone T, Gridelli C, Ciardiello F: Combined targeted therapies in non-small cell lung cancer: a winner strategy? Curr Opin Oncol. 2007 Mar;19(2):98-102.@@Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A: Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist. 2007 Feb;12(2):191-200.@@Lu X, Tang X, Guo W, Ren T, Zhao H: Sorafenib induces growth inhibition and apoptosis of human chondrosarcoma cells by blocking the RAF/ERK/MEK pathway. J Surg Oncol. 2010 Dec 1;102(7):821-6. doi: 10.1002/jso.21661.@@Smalley KS, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Van Belle P, Elder DE, Wang Y, Nathanson KL, Herlyn M: CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutations. Oncogene. 2009 Jan 8;28(1):85-94. doi: 10.1038/onc.2008.362. Epub 2008 Sep 15.@@Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M: Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008 Oct;7(10):3129-40. doi: 10.1158/1535-7163.MCT-08-0013.@@Iyer R, Fetterly G, Lugade A, Thanavala Y: Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. |
| Groups | Approved; Investigational |
| Direct Classification | Diarylethers |
| SMILES | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
| Pathways | Sorafenib Metabolism Pathway |
| PharmGKB | PA7000 |
| ChEMBL | CHEMBL1336 |
